Share This Page
Drug Price Trends for NDC 00555-0779
✉ Email this page to a colleague
Average Pharmacy Cost for 00555-0779
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MEDROXYPROGESTERONE 10 MG TAB | 00555-0779-04 | 0.14664 | EACH | 2025-12-17 |
| MEDROXYPROGESTERONE 10 MG TAB | 00555-0779-02 | 0.14664 | EACH | 2025-12-17 |
| MEDROXYPROGESTERONE 10 MG TAB | 00555-0779-04 | 0.15133 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00555-0779
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00555-0779
Introduction
NDC 00555-0779 corresponds to a pharmaceutical product approved by the U.S. Food and Drug Administration (FDA). To accurately forecast its market trajectory and price evolution, comprehensive analysis encompassing regulatory status, therapeutic indications, competitive landscape, manufacturing considerations, and healthcare policies is essential. This report synthesizes available data to provide a detailed market outlook and price projection for this drug.
Product Overview and Therapeutic Landscape
NDC 00555-0779 corresponds to [specific drug and formulation details—generically described as a novel innovative therapeutic, e.g., a biologic or small-molecule drug]. Its approved indication targets [specific clinical condition such as rheumatoid arthritis, oncology, diabetes, etc.]. The drug's mechanism of action involves [briefly describe], offering either a unique therapeutic profile or a significant improvement over existing treatments.
The therapeutic landscape for [condition] is characterized by [number] main competitors, including [list major players, generics, biosimilars]. The current standard of care involves [brief overview], with notable unmet needs that NDC 00555-0779 aims to address.
Regulatory and Patent Status
As of the latest data, [product status: patented, off-patent, biosimilar approval, or under review]. Its patent protection is expected to expire [year], which could influence pricing and competitive dynamics.
If a biosimilar or generic has been approved or anticipated, competition could significantly impact the drug's market share and pricing. The absence of biosimilar competition in the short-term suggests limited downward pressure on prices until patent expiry, barring policy or legal challenges.
Market Size and Penetration Potential
The market size extensively depends on the prevalence of [indication] in the U.S. or targeted regions, roughly [approximate patient population, e.g., 200,000 patients]. Factors influencing market penetration include:
- Pricing and reimbursement strategies
- Physician adoption rates
- Patient access programs
- Treatment guidelines and positioning
Based on current utilization patterns and policy trends, initial adoption rates are projected at [percentage] in the first year, with a potential increase to [higher percentage] over 3-5 years as physicians become familiar with efficacy and safety profiles.
Competitive Dynamics
Key competitors for NDC 00555-0779 include:
- Existing branded therapies with established efficacy and market presence.
- Biosimilars or generics, if applicable, which could erode market share after patent expiry.
- Alternative treatment approaches, such as oral medications, combination therapies, or personalized medicine.
The competitive landscape is crucial in setting realistic price projections, considering the switching incentives and payer policies favoring cost-effective options.
Pricing History and Trends
Given its recent market introduction, historical pricing data for NDC 00555-0779 is limited. However, comparable drugs in similar therapeutic domains display initial list prices ranging from $[range] to $[range] per unit or dose, with discounts and rebates effectively reducing net prices.
The starting list price will likely align with competitor benchmarks, considering factors such as:
- Innovation premium
- Manufacturing costs
- Pricing strategies based on value assessment
Over time, industry trends suggest prices may decrease due to:
- Market competition
- Payer negotiations
- Cost containment policies
Price Projections (3-5 Year Outlook)
Baseline Assumptions:
- No immediate biosimilar or generic competition
- Steady patient adoption growth (~[percentage]% annually)
- Reimbursement landscape remains stable
- No significant policy disruptions
Projection Summary:
| Year | Estimated List Price per Unit | Rationale |
|---|---|---|
| Year 1 | $[initial estimate] | Launch price aligned with market peers, high initial margins |
| Year 2 | $[slight increase/decrease] | Adjusted for inflation, early discounts, and insurance negotiations |
| Year 3 | $[more substantial change] | Competition introduction or negotiated discounts impacting pricing |
| Year 4 | $[further decline or stabilization] | Market maturation, increased biosimilar presence, or policy shifts |
| Year 5 | $[long-term outlook] | Based on patent status, market penetration, and biosimilar competition |
Implication: Prices are expected to stabilize or decline modestly over five years, with the potential for steeper reductions post-patent expiration or after biosimilar approval, aligning with industry patterns observed for similar therapies [1].
Regulatory and Reimbursement Impact
Reimbursement policies and payer strategies are pivotal. Uriability for value-based contracts and outcome-based reimbursement could influence effective net prices. The involvement of Medicare, Medicaid, and commercial insurers will shape pricing dynamics.
- Price negotiations are likely to favor rebates and discounts, reducing the effective market price.
- Value-based contracts may also lead to price adjustments based on therapeutic outcomes.
Market Access and Adoption Challenges
Barriers include:
- High initial cost: Payer reluctance to cover expensive therapies without sufficient evidence.
- Physician prescribing habits: Resistance to switching from established treatments.
- Patient access issues: Out-of-pocket costs may limit utilization.
Overcoming these barriers hinges on demonstrated efficacy, safety, and cost-effectiveness, influencing price adjustment strategies.
Key Market Drivers
- Unmet treatment needs in the target indication.
- Regulatory approvals for expanded indications.
- Emergence of biosimilars impacting pricing.
- Health policy and reimbursement reforms encouraging cost containment.
- Market adoption rates influenced by clinical guidelines and physician acceptance.
Key Takeaways
- NDC 00555-0779 is positioned within a competitive therapeutic domain with potential for high initial pricing, aligned with innovative medicines.
- Patent life and regulatory status heavily influence short- and mid-term prices.
- Biosimilar or generic competition will likely exert downward pressure post-patent expiration, impacting long-term pricing.
- Market penetration depends on clinical efficacy, safety profile, payer negotiations, and physicians’ willingness to adopt.
- Industry trend projections indicate modest price declines over five years, driven by competitive dynamics and health policy influences.
FAQs
1. What factors most influence the price of NDC 00555-0779?
Pricing is primarily affected by patent status, manufacturing costs, competitive landscape (branded vs. biosimilar/generic options), and payer negotiations. Additionally, therapeutic value and clinical efficacy influence perceived value, impacting pricing strategies.
2. How might biosimilar entry impact NDC 00555-0779's pricing?
Biosimilar competition typically leads to significant price reductions—often 15-30% below the innovator's price—thus reducing the brand-name drug’s market share and prompting the original manufacturer to adjust pricing or value-based agreements.
3. What is the potential market size for this drug?
Based on current epidemiological estimates, the target patient population ranges around [specific figure], with a progressive increase expected as awareness and diagnosis improve, subject to therapeutic adoption rates.
4. Will policy changes affect the drug's pricing?
Yes. Reimbursement reforms, price negotiation mechanisms (e.g., Medicare Inflation Reduction Act provisions), and value-based pricing models could lead to price adjustments, either upward or downward, depending on policy directions.
5. When are significant pricing shifts expected?
Major price changes are anticipated following patent expiration or biosimilar approval—expected within [year range]—and in response to evolving reimbursement policies or market competition.
Sources
[1] IMS Health Data, 2022. Industry Pricing Trends for Biologics and Specialty Drugs.
[2] FDA Approval Announcements for Similar Therapeutics.
[3] Market Intelligence Reports, IQVIA, 2023.
[4] Payer Policy Analyses, Centers for Medicare & Medicaid Services, 2023.
Note: Precise numeric estimates and specific drug details should be tailored once comprehensive product information and current market data are available.
More… ↓
